401 related articles for article (PubMed ID: 25797560)
1. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Kipps TJ; Eradat H; Grosicki S; Catalano J; Cosolo W; Dyagil IS; Yalamanchili S; Chai A; Sahasranaman S; Punnoose E; Hurst D; Pylypenko H
Leuk Lymphoma; 2015; 56(10):2826-33. PubMed ID: 25797560
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
[TBL] [Abstract][Full Text] [Related]
3. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
6. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
Robak T; Błoński J; Skotnicki AB; Piotrowska M; Wróbel T; Rybka J; Kłoczko J; Bołkun Ł; Budziszewska BK; Walczak U; Uss A; Fidecka M; Smolewski P
Eur J Haematol; 2018 May; 100(5):465-474. PubMed ID: 29427355
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
[TBL] [Abstract][Full Text] [Related]
12. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
Yalniz FF; Wierda WG
Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
[TBL] [Abstract][Full Text] [Related]
15. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
16. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
O'Brien SM; Lamanna N; Kipps TJ; Flinn I; Zelenetz AD; Burger JA; Keating M; Mitra S; Holes L; Yu AS; Johnson DM; Miller LL; Kim Y; Dansey RD; Dubowy RL; Coutre SE
Blood; 2015 Dec; 126(25):2686-94. PubMed ID: 26472751
[TBL] [Abstract][Full Text] [Related]
19. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
[TBL] [Abstract][Full Text] [Related]
20. Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors.
Smith ML; Chyla B; McKeegan E; Tahir SK
Cytometry B Clin Cytom; 2017 Sep; 92(5):331-339. PubMed ID: 27177607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
